A new polycythaemia vera-associated SOCS3 SH2 mutant (SOCS3 F136L) cannot regulate erythropoietin responses

British Journal of Haematology

Volumn 147, Issue 4, 2009, Pages 450-458

  Suessmuth, Yvonne ^a   Elliott, Joanne ^a   Percy, Melanie J ^b   Inami, Mitsuharu ^c   Attal, Hila ^d   Harrison, Claire N ^e   Inokuchi, Koiti ^c   McMullin, Mary Frances ^a   Johnston, James A ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b BELFAST CITY HOSPITAL   (United Kingdom)

^c NIPPON MEDICAL SCHOOL   (Japan)

^d SHEBA MEDICAL CENTER   (Israel)

^e ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Erythropoietin; Exon 12; JAK2 mutation; Myeloproliferative disorders; Polycythaemia vera; SOCS3 mutation

Indexed keywords

ERYTHROPOIETIN; JANUS KINASE 2; PHOSPHOPROTEIN; PROTEIN SH2; SUPPRESSOR OF CYTOKINE SIGNALING 3;

ADULT; ANIMAL CELL; ARTICLE; CASE REPORT; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FEMALE; GENE DELETION; GENE FUNCTION; GERM LINE; HALF LIFE TIME; HETEROZYGOSITY; HUMAN; HUMAN CELL; JAPANESE; MOUSE; MYELOPROLIFERATIVE DISORDER; NONHUMAN; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN STABILITY; SIGNAL TRANSDUCTION; SOMATIC MUTATION; WILD TYPE;

ADULT; BASE SEQUENCE; CELL PROLIFERATION; CELLS, CULTURED; ERYTHROPOIETIN; FEMALE; GERM-LINE MUTATION; HUMANS; JANUS KINASE 2; MUTATION; PHOSPHORYLATION; POLYCYTHEMIA VERA; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 70350455110     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2009.07860.x     Document Type: Article

References (26)

1. Babon, J.J., Yao, S., DeSouza, D.P., Harrison, C.F., Fabri, L.J., Liepinsh, E., Scrofani, S.D., Baca, M. Norton, R.S. (2005) Secondary structure assignment of mouse SOCS3 by NMR defines the domain boundaries and identifies an unstructured insertion in the SH2 domain. The FEBS Journal, 272, 6120 6130.
2. Babon, J.J., McManus, E.J., Yao, S., DeSouza, D.P., Mielke, L.A., Sprigg, N.S., Willson, T.A., Hilton, D.J., Nicola, N.A., Baca, M., Nicholson, S.E. Norton, R.S. (2006) The structure of SOCS3 reveals the basis of the extended SH2 domain function and identifies an unstructured insertion that regulates stability. Molecular Cell, 22, 205 216.
3. Cacalano, N.A., Sanden, D. Johnston, J.A. (2001) Tyrosine-phosphorylated SOCS-3 inhibits STAT activation but binds to p120 RasGAP and activates ras. Nature Cell Biology, 3, 460 465.
4. Cohney, S.J., Sanden, D., Cacalano, N.A., Yoshimura, A., Mui, A., Migone, T.S. Johnston, J.A. (1999) SOCS-3 is tyrosine phosphorylated in response to interleukin-2 and suppresses STAT5 phosphorylation and lymphocyte proliferation. Molecular and Cellular Biology, 19, 4980 4988.
5. Dusa, A., Staerk, J., Elliott, J., Pecquet, C., Poirel, H.A., Johnston, J.A. Constantinescu, S.N. (2008) Substitution of pseudokinase domain residue val-617 by large non-polar amino acids causes activation of JAK2. The Journal of Biological Chemistry, 283, 12941 12948.
6. Elliott, J., Suessmuth, Y., Scott, L.M., Nahlik, K., McMullin, M.F., Constantinescu, S.N., Green, A.R. Johnston, J.A. (2009) SOCS3 tyrosine phosphorylation as a potential bio-marker for myeloproliferative neoplasms associated with mutant JAK2 kinases. Haematologica, 94, 576 580.
7. Haan, S., Ferguson, P., Sommer, U., Hiremath, M., McVicar, D.W., Heinrich, P.C., Johnston, J.A. Cacalano, N.A. (2003) Tyrosine phosphorylation disrupts elongin interaction and accelerates SOCS3 degradation. The Journal of Biological Chemistry, 278, 31972 31979.
8. Hookham, M.B., Elliott, J., Suessmuth, Y., Staerk, J., Ward, A.C., Vainchenker, W., Percy, M.J., McMullin, M.F., Constantinescu, S.N. Johnston, J.A. (2007) The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3. Blood, 109, 4924 4929.
9. Kornitzer, D., Raboy, B., Kulka, R.G. Fink, G.R. (1994) Regulated degradation of the transcription factor Gcn4. The EMBO Journal, 13, 6021 6030.
10. Kralovics, R., Passamonti, F., Buser, A.S., Teo, S.S., Tiedt, R., Passweg, J.R., Tichelli, A., Cazzola, M. Skoda, R.C. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. The New England Journal of Medicine, 352, 1779 1790. (Pubitemid 40570926)
11. Limnander, A., Danial, N.N. Rothman, P.B. (2004) v-abl signaling disrupts SOCS-1 function in transformed pre-B cells. Molecular Cell, 15, 329 341.
12. Nicholson, S.E., Willson, T.A., Farley, A., Starr, R., Zhang, J.G., Baca, M., Alexander, W.S., Metcalf, D., Hilton, D.J. Nicola, N.A. (1999) Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibition of LIF and IL-6 signal transduction. The EMBO Journal, 18, 375 385.
13. Nicholson, S.E., De Souza, D., Fabri, L.J., Corbin, J., Willson, T.A., Zhang, J.G., Silva, A., Asimakis, M., Farley, A., Nash, A.D., Metcalf, D., Hilton, D.J., Nicola, N.A. Baca, M. (2000) Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130. Proceedings of the National Academy of Sciences of the United States of America, 97, 6493 6498.
14. Orr, S.J., Morgan, N.M., Elliott, J., Burrows, J.F., Scott, C.J., McVicar, D.W. Johnston, J.A. (2007a) CD33 responses are blocked by SOCS3 through accelerated proteasomal-mediated turnover. Blood, 109, 1061 1068.
15. Orr, S.J., Morgan, N.M., Buick, R.J., Boyd, C.R., Elliott, J., Burrows, J.F., Jefferies, C.A., Crocker, P.R. Johnston, J.A. (2007b) SOCS3 targets siglec 7 for proteasomal degradation and blocks siglec 7-mediated responses. The Journal of Biological Chemistry, 282, 3418 3422.
16. Pietra, D., Li, S., Brisci, A., Passamonti, F., Rumi, E., Theocharides, A., Ferrari, M., Gisslinger, H., Kralovics, R., Cremonesi, L., Skoda, R. Cazzola, M. (2008) Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood, 111, 1686 1689.
17. Prakash, S., Tian, L., Ratliff, K.S., Lehotzky, R.E. Matouschek, A. (2004) An unstructured initiation site is required for efficient proteasome-mediated degradation. Nature Structural & Molecular Biology, 11, 830 837.
18. Rechsteiner, M. Rogers, S.W. (1996) PEST sequences and regulation by proteolysis. Trends in Biochemical Sciences, 21, 267 271.
19. Remy, I., Wilson, I.A. Michnick, S.W. (1999) Erythropoietin receptor activation by a ligand-induced conformation change. Science (New York, NY), 283, 990 993.
20. Richmond, T.D., Chohan, M. Barber, D.L. (2005) Turning cells red: signal transduction mediated by erythropoietin. Trends in Cell Biology, 15, 146 155.
21. Saharinen, P., Vihinen, M. Silvennoinen, O. (2003) Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain. Molecular Biology of the Cell, 14, 1448 1459.
22. Sasaki, A., Yasukawa, H., Suzuki, A., Kamizono, S., Syoda, T., Kinjyo, I., Sasaki, M., Johnston, J.A. Yoshimura, A. (1999) Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) inhibits janus tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain. Genes to Cells: Devoted to Molecular & Cellular Mechanisms, 4, 339 351.
23. Sasaki, A., Yasukawa, H., Shouda, T., Kitamura, T., Dikic, I. Yoshimura, A. (2000) CIS3/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2. The Journal of Biological Chemistry, 275, 29338 29347.
24. Scott, L.M., Tong, W., Levine, R.L., Scott, M.A., Beer, P.A., Stratton, M.R., Futreal, P.A., Erber, W.N., McMullin, M.F., Harrison, C.N., Warren, A.J., Gilliland, D.G., Lodish, H.F. Green, A.R. (2007) JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. The New England Journal of Medicine, 356, 459 468.
25. Tannahill, G.M., Elliott, J., Barry, A.C., Hibbert, L., Cacalano, N.A. Johnston, J.A. (2005) SOCS2 can enhance interleukin-2 (IL-2) and IL-3 signaling by accelerating SOCS3 degradation. Molecular and Cellular Biology, 25, 9115 9126.
26. Tiedt, R., Hao-Shen, H., Sobas, M.A., Looser, R., Dirnhofer, S., Schwaller, J. Skoda, R.C. (2008) Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood, 111, 3931 3940.